Transarterial chemoembolization plus a PD-1 inhibitor with or without lenvatinib for intermediate-stage hepatocellular carcinoma.

Yan-Jun XiangKang WangHong-Ming YuXiao-Wei LiYu-Qiang ChengWei-Jun WangJin-Kai FengMeng-Han BoYing-Yi QinYi-Tao ZhengYun-Feng ShanLi-Ping ZhouJian ZhaiShu-Qun Cheng

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2022)

The combination of TACE with a PD-1 inhibitor and lenvatinib in patients with BCLC stage B HCC might result in significantly improved clinical outcomes with a manageable safety profile compared with TACE with a PD-1 inhibitor.

Keyphrases

radiofrequency ablation
liver metastases